Colorectal cancer (CRC) is presently one of the most common causes of cancer‐related
death in our setting and affects a great number of people each year. Screening strategies …

Abstract Selective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the
anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory …

Abstract The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of
the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention …

Large bowel cancer is not only the third most frequent cancer in the world but is one of the
most common human malignancies in Western countries, including North America. In recent …

There is considerable interest in the involvement of cyclooxygenase-2 (COX-2) in colon
carcinogenesis and its progression, because nonsteroidal anti-inflammatory drugs (NSAIDs) …

BACKGROUND & AIMS:: Colorectal cancer is one of the leading causes of cancer death.
Most colorectal cancers are believed to develop from colorectal adenomas. We examined …

The positive association of decreased risk of colorectal cancer with nonsteroidal
antiinflammatory drug (NSAID) use, combined with the observation that cyclooxygenase …

The finding that cyclooxygenase-2 (COX-2) is over-expressed and plays an important role in
carcinogenesis in gastrointestinal (GI) cancers including esophagus, gastric and colorectal …

More than 40 promising agents and agent combinations are being evaluated clinically as
chemopreventive drugs for major cancer targets. A few have been in vanguard, large‐scale …

NSAIDs (non-steroidal anti-inflammatory drugs) prevent colon and other cancers. The fact
that NSAIDs inhibit the eicosanoid pathway prompted mechanistic drug-developmental work …